Frontiers 22 Bergamo: Complement Related Kidney Diseases - Classification, Genetics and Treatment
The ISN Frontiers Meeting ‘Complements related kidney diseases: classification, genetics and treatment’ will give scientists engaged in rare diseases - specifically in the field of complement-mediated kidney diseases - the opportunity to speed up research and drug development in the field.
The meeting will focus on the 2 prototypical complement-mediated kidney diseases: atypical hemolytic uremic syndrome (aHUS) and C3 Glomerulopathies/Membranoproliferative Glomerulonephritis (C3G/MPGN), both very rare and severe diseases. aHUS is an ultra-rare disease with an estimated prevalence of 1/100,000), while primary C3G/MPGN has an estimated prevalence of 16/100,000.
Despite current available treatments, key issues regarding diagnosis and genetic assessment remain a challenge. It is urgently required to provide an analysis of the state of the art on the knowledge advancement, to identify key issues relevant to the optimal management of these two diseases and to propose a research agenda to resolve outstanding controversial issues.
Driven by this, the meeting will gather a global panel of clinical and scientific expertise, bringing clinicians, scientists, academics and general practitioners face to face by sharing and presenting the latest developments in terms of disease classification and genetics and identifying knowledge gaps and unmet treatment needs with the final aim of improving the health and well-being of kidney rare disease patients worldwide. This is perfectly in line with the ISN mission of advancing worldwide kidney health. By bringing together and fostering connections between different experts in rare complement mediated kidney diseases, the meeting will contribute to strengthen existing and establish new collaborations that will enhance the skills and expertise in the field and offer evidence-based suggestions for future research.